

Frédérique M Penault-Llorca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4444711/publications.pdf>

Version: 2024-02-01

193
papers

27,809
citations

20036

63
h-index

6686

161
g-index

252
all docs

252
docs citations

252
times ranked

33320
citing authors

#	ARTICLE	IF	CITATIONS
1	Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130. <i>Journal of the National Cancer Institute</i> , 2022, 114, 664-675.	3.0	31
2	PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers. <i>Cancers</i> , 2022, 14, 599.	1.7	8
3	Abstract P1-08-24: Platelet-to-lymphocyte ratio is worth using with tumor-infiltrating lymphocytes to predict good response to neoadjuvant chemotherapy in triple negative breast cancer: A study on 120 patients. <i>Cancer Research</i> , 2022, 82, P1-08-24-P1-08-24.	0.4	0
4	COVID-19 Infections in Cancer Patients Were Frequently Asymptomatic: Description From a French Prospective Multicenter Cohort (PAPESCO-19). <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492210901.	0.6	3
5	Effects of GSK-J4 on JMJD3 Histone Demethylase in Mouse Prostate Cancer Xenografts. <i>Cancer Genomics and Proteomics</i> , 2022, 19, 339-349.	1.0	6
6	Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3699-3708.	0.8	11
7	Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib. <i>BMC Cancer</i> , 2022, 22, .	1.1	6
8	Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. <i>Lancet Oncology</i> , The, 2021, 22, e18-e28.	5.1	49
9	Synthesis and <i>in vitro</i> preliminary evaluation of prostate-specific membrane antigen targeted upconversion nanoparticles as a first step towards radio/fluorescence-guided surgery of prostate cancer. <i>Journal of Materials Chemistry B</i> , 2021, 9, 7423-7434.	2.9	13
10	Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098765.	1.4	13
11	Why is appropriate healthcare inaccessible for many European breast cancer patients? – The EBCC 12 manifesto. <i>Breast</i> , 2021, 55, 128-135.	0.9	18
12	Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 311-325.	1.3	19
13	Role of UTX Histone Demethylase in Regulation of MGMT, TRA2A, U2AF1, and RPS6KA2 Genes in Prostate Cancer Cell Lines. <i>OMICS A Journal of Integrative Biology</i> , 2021, 25, 129-131.	1.0	2
14	Implementation of the TIP60/P400/H4K12ac Structure in Breast Cancer Cell Lines. <i>OMICS A Journal of Integrative Biology</i> , 2021, 25, 202-205.	1.0	0
15	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. <i>European Journal of Cancer</i> , 2021, 146, 30-47.	1.3	81
16	Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 2262.	1.7	9
17	Reproducibility of mRNA-Based Testing of ESR1, PGR, ERBB2, and MKI67 Expression in Invasive Breast Cancer – A Europe-Wide External Quality Assessment. <i>Cancers</i> , 2021, 13, 4718.	1.7	6
18	Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis. <i>Breast</i> , 2021, 59, 183-192.	0.9	10

#	ARTICLE	IF	CITATIONS
19	Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. <i>Journal of the National Cancer Institute</i> , 2021, 113, 808-819.	3.0	319
20	Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance. <i>Gastric Cancer</i> , 2020, 23, 73-81.	2.7	75
21	Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 735-741.	1.2	25
22	The Inhibition of the Histone Methyltransferase EZH2 by DZNEP or SiRNA Demonstrates Its Involvement in <i>MGMT</i> , <i>TRA2A</i> , <i>RPS6KA2</i> , and <i>U2AF1</i> Gene Regulation in Prostate Cancer. <i>OMICS A Journal of Integrative Biology</i> , 2020, 24, 116-118.	1.0	7
23	Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG) Tj ETQq1 1 0.784314 rBT /Over	0.7	14
24	Digging Deeper into Breast Cancer Epigenetics: Insights from Chemical Inhibition of Histone Acetyltransferase TIP60 <i>In Vitro</i> . <i>OMICS A Journal of Integrative Biology</i> , 2020, 24, 581-591.	1.0	2
25	Progresses Toward Precision Medicine in <i>RET</i> -altered Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 6102-6111.	3.2	39
26	TIP60/P400/H4K12ac Plays a Role as a Heterochromatin Back-up Skeleton in Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 687-694.	1.0	5
27	Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2020, 396, 1090-1100.	6.3	625
28	Epi-drugs as triple-negative breast cancer treatment. <i>Epigenomics</i> , 2020, 12, 725-742.	1.0	9
29	Role of JMJD3 Demethylase and Its Inhibitor GSK-J4 in Regulation of <i>MGMT</i> , <i>TRA2A</i> , <i>RPS6KA2</i> , and <i>U2AF1</i> Genes in Prostate Cancer Cell Lines. <i>OMICS A Journal of Integrative Biology</i> , 2020, 24, 505-507.	1.0	9
30	Role of Hormones in Common Benign Uterine Lesions: Endometrial Polyps, Leiomyomas, and Adenomyosis. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1242, 37-58.	0.8	15
31	TIP60 Inhibitor TH1834 Reduces Breast Cancer Progression in Xenografts in Mice. <i>OMICS A Journal of Integrative Biology</i> , 2019, 23, 457-459.	1.0	12
32	Breast cancer. <i>Nature Reviews Disease Primers</i> , 2019, 5, 66.	18.1	1,620
33	Implementing TMB measurement in clinical practice: considerations on assay requirements. <i>ESMO Open</i> , 2019, 4, e000442.	2.0	257
34	FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. <i>European Journal of Cancer</i> , 2019, 115, 97-106.	1.3	29
35	Testing algorithm for identification of patients with TRK fusion cancer. <i>Journal of Clinical Pathology</i> , 2019, 72, 460-467.	1.0	137
36	Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. <i>Histopathology</i> , 2019, 75, 225-235.	1.6	74

#	ARTICLE	IF	CITATIONS
37	The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines. <i>Journal of Clinical Medicine</i> , 2019, 8, 397.	1.0	8
38	Impact of Chemotherapy-induced Menopause in Women of Childbearing Age With Non-metastatic Breast Cancer – Preliminary Results From the MENOCOR Study. <i>Clinical Breast Cancer</i> , 2019, 19, e74-e84.	1.1	14
39	Development and validation of a high-performance liquid chromatography method for the quantitation of intracellular PARP inhibitor Olaparib in cancer cells. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 152, 74-80.	1.4	19
40	Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ. <i>BMC Cancer</i> , 2018, 18, 129.	1.1	40
41	SIRT1 in Colorectal Cancer: A Friend or Foe?. <i>OMICS A Journal of Integrative Biology</i> , 2018, 22, 298-300.	1.0	6
42	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. <i>Seminars in Cancer Biology</i> , 2018, 52, 16-25.	4.3	303
43	Tumor mutational burden in non-small cell lung cancer – the pathologist’s point of view. <i>Translational Lung Cancer Research</i> , 2018, 7, 716-721.	1.3	10
44	TIP60: an actor in acetylation of H3K4 and tumor development in breast cancer. <i>Epigenomics</i> , 2018, 10, 1415-1430.	1.0	20
45	Breaking down the Contradictory Roles of Histone Deacetylase SIRT1 in Human Breast Cancer. <i>Cancers</i> , 2018, 10, 409.	1.7	26
46	The Dilemma of HER2 Double-equivocal Breast Carcinomas. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1190-1200.	2.1	20
47	High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast. <i>Histopathology</i> , 2018, 73, 273-283.	1.6	33
48	The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial). <i>BMC Cancer</i> , 2018, 18, 526.	1.1	24
49	Exciting History of Tip60 and Its Companions in Carcinogenesis Across the Heterochromatin Landscapes. <i>OMICS A Journal of Integrative Biology</i> , 2018, 22, 626-628.	1.0	6
50	A new metabolic gene signature in prostate cancer regulated by JMJD3 and EZH2. <i>Oncotarget</i> , 2018, 9, 23413-23425.	0.8	27
51	SIRT1-dependent epigenetic regulation of H3 and H4 histone acetylation in human breast cancer. <i>Oncotarget</i> , 2018, 9, 30661-30678.	0.8	44
52	miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers. <i>Pathology and Oncology Research</i> , 2017, 23, 815-827.	0.9	32
53	Ki67 assessment in breast cancer: an update. <i>Pathology</i> , 2017, 49, 166-171.	0.3	157
54	PL04a.04: Multicentric French Harmonization Study for PD-L1 IHC Testing in NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, S11-S12.	0.5	29

#	ARTICLE	IF	CITATIONS
55	A stemness-related ZEB1-MSRB3 axis governs cellular plasticity and breast cancer genome stability. <i>Nature Medicine</i> , 2017, 23, 568-578.	15.2	131
56	p-gp expression levels in the erythrocytes of brown trout: a new tool for aquatic sentinel biomarker development. <i>Biomarkers</i> , 2017, 22, 566-574.	0.9	4
57	Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw272.	3.0	201
58	Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. <i>Seminars in Oncology</i> , 2017, 44, 187-197.	0.8	76
59	TIP60 Histone Acetyltransferase in Adipose Tissue: Possible Linkages with Breast Cancer Development?. <i>OMICS A Journal of Integrative Biology</i> , 2017, 21, 684-686.	1.0	1
60	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 311-338.	2.4	530
61	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 225-251.	2.4	469
62	EZH2 Histone Methyltransferase and JMJD3 Histone Demethylase Implications in Prostate Cancer. <i>OMICS A Journal of Integrative Biology</i> , 2017, 21, 751-753.	1.0	5
63	Daily Practice Management of pT1a-b pN0 Breast Carcinoma: A Prospective French ODISSEE Cohort Study. <i>Clinical Breast Cancer</i> , 2017, 17, 107-116.	1.1	1
64	Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells. <i>Molecular Carcinogenesis</i> , 2017, 56, 1383-1394.	1.3	13
65	Quantification of hypoxia-related gene expression as a potential approach for clinical outcome prediction in breast cancer. <i>PLoS ONE</i> , 2017, 12, e0175960.	1.1	13
66	Dual SIRT1 expression patterns strongly suggests its bivalent role in human breast cancer. <i>Oncotarget</i> , 2017, 8, 110922-110930.	0.8	32
67	Development and cytotoxic response of two proliferative MDA-MB-231 and non-proliferative SUM1315 three-dimensional cell culture models of triple-negative basal-like breast cancer cell lines. <i>Oncotarget</i> , 2017, 8, 95316-95331.	0.8	35
68	Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3867-3876.	0.8	343
69	Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers. <i>PLoS ONE</i> , 2017, 12, e0185753.	1.1	15
70	TERT promoter status and gene copy number gains: effect on TERT expression and association with prognosis in breast cancer. <i>Oncotarget</i> , 2017, 8, 77540-77551.	0.8	34
71	Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer. <i>Oncotarget</i> , 2016, 7, 73618-73637.	0.8	77
72	Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer. <i>Laryngoscope</i> , 2016, 126, E156-63.	1.1	24

#	ARTICLE	IF	CITATIONS
73	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. <i>Modern Pathology</i> , 2016, 29, 1155-1164.	2.9	230
74	Testing for ROS1 in non-small cell lung cancer: a review with recommendations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 489-503.	1.4	190
75	H3K4 acetylation, H3K9 acetylation and H3K27 methylation in breast tumor molecular subtypes. <i>Epigenomics</i> , 2016, 8, 909-924.	1.0	28
76	ERCC1 and telomere status in breast tumours treated with neoadjuvant chemotherapy and their association with patient prognosis. <i>Journal of Pathology: Clinical Research</i> , 2016, 2, 234-246.	1.3	18
77	Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. <i>Npj Breast Cancer</i> , 2016, 2, 16014.	2.3	109
78	Molecular and Epigenetic Biomarkers in Luminal Androgen Receptor: A Triple Negative Breast Cancer Subtype. <i>OMICS A Journal of Integrative Biology</i> , 2016, 20, 610-613.	1.0	4
79	Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). <i>Lancet, The</i> , 2016, 387, 1415-1426.	6.3	790
80	The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. <i>Autophagy</i> , 2016, 12, 864-875.	4.3	90
81	The JMJD3 Histone Demethylase and the EZH2 Histone Methyltransferase in Prostate Cancer. <i>OMICS A Journal of Integrative Biology</i> , 2016, 20, 123-125.	1.0	13
82	Biomarkers of residual disease after neoadjuvant therapy for breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 487-503.	12.5	43
83	High-throughput «Omics» technologies: New tools for the study of triple-negative breast cancer. <i>Cancer Letters</i> , 2016, 382, 77-85.	3.2	29
84	Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 205-214.	1.2	23
85	Epigenetic Modifications with DZNep, NaBu and SAHA in Luminal and Mesenchymal-like Breast Cancer Subtype Cells. <i>Cancer Genomics and Proteomics</i> , 2016, 13, 291-303.	1.0	6
86	Cellular Expression of Cyclooxygenase, Aromatase, Adipokines, Inflammation and Cell Proliferation Markers in Breast Cancer Specimen. <i>PLoS ONE</i> , 2015, 10, e0138443.	1.1	16
87	Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 88-104.	2.0	72
88	Is It Important to Adapt Neoadjuvant Chemotherapy to the Visible Clinical Response? An Open Randomized Phase II Study Comparing Response-Guided and Standard Treatments in HER2-Negative Operable Breast Cancer. <i>Oncologist</i> , 2015, 20, 243-244.	1.9	4
89	Mini-P-gp and P-gp Co-Expression in Brown Trout Erythrocytes: A Prospective Blood Biomarker of Aquatic Pollution. <i>Diagnostics</i> , 2015, 5, 10-26.	1.3	2
90	A bivalent role of TIP60 histone acetyl transferase in human cancer. <i>Epigenomics</i> , 2015, 7, 1351-1363.	1.0	57

#	ARTICLE	IF	CITATIONS
91	Prostate cancer: The main risk and protective factors—Epigenetic modifications. <i>Annales D'Endocrinologie</i> , 2015, 76, 25-41.	0.6	32
92	Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. <i>Modern Pathology</i> , 2015, 28, 1185-1201.	2.9	205
93	Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study. <i>Oncologist</i> , 2015, 20, 873-879.	1.9	43
94	Genome-Wide DNA Methylation Modified by Soy Phytoestrogens: Role for Epigenetic Therapeutics in Prostate Cancer?. <i>OMICS A Journal of Integrative Biology</i> , 2015, 19, 209-219.	1.0	28
95	The Role of Sentinel Lymph Node Biopsy and Factors Associated with Invasion in Extensive DCIS of the Breast Treated by Mastectomy: The Cinnamome Prospective Multicenter Study. <i>Annals of Surgical Oncology</i> , 2015, 22, 3853-3860.	0.7	34
96	An international study to increase concordance in Ki67 scoring. <i>Modern Pathology</i> , 2015, 28, 778-786.	2.9	195
97	French multicentric validation of <i>ALK</i> rearrangement diagnostic in 547 lung adenocarcinomas. <i>European Respiratory Journal</i> , 2015, 46, 207-218.	3.1	54
98	Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. <i>Autophagy</i> , 2015, 11, 1878-1890.	4.3	91
99	The Role of Soy Phytoestrogens on Genetic and Epigenetic Mechanisms of Prostate Cancer. <i>The Enzymes</i> , 2015, 37, 193-221.	0.7	7
100	Molecular Ultrasound Imaging Using Contrast Agents Targeting Endoglin, Vascular Endothelial Growth Factor Receptor 2 and Integrin. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 197-207.	0.7	28
101	BRCA1 Induces Major Energetic Metabolism Reprogramming in Breast Cancer Cells. <i>PLoS ONE</i> , 2014, 9, e102438.	1.1	54
102	HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. <i>Oncotarget</i> , 2014, 5, 7138-7148.	0.8	43
103	Epigenetics of Prostate Cancer: Distribution of Histone H3K27me3 Biomarkers in Peri-Tumoral Tissue. <i>OMICS A Journal of Integrative Biology</i> , 2014, 18, 207-209.	1.0	14
104	Morphological and immunohistochemical pattern of tubo-ovarian dysplasia and serous tubal intraepithelial carcinoma. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2014, 183, 89-95.	0.5	9
105	Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer. <i>Science Signaling</i> , 2014, 7, ra29.	1.6	123
106	Epigenetic mechanisms of breast cancer: an update of the current knowledge. <i>Epigenomics</i> , 2014, 6, 651-664.	1.0	83
107	Lung Cancer Stem Cell: Fancy Conceptual Model of Tumor Biology or Cornerstone of a Forthcoming Therapeutic Breakthrough?. <i>Journal of Thoracic Oncology</i> , 2014, 9, 7-17.	0.5	31
108	Multicenter Immunohistochemical ALK-Testing of Non-Small-Cell Lung Cancer Shows High Concordance after Harmonization of Techniques and Interpretation Criteria. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1685-1692.	0.5	66

#	ARTICLE	IF	CITATIONS
109	Comparative Effects of Soy Phytoestrogens and 17 β -Estradiol on DNA Methylation of a Panel of 24 Genes in Prostate Cancer Cell Lines. <i>Nutrition and Cancer</i> , 2014, 66, 474-482.	0.9	16
110	Risk of Breast Cancer by Individual Insulin Use: An International Multicenter Study. <i>Diabetes Care</i> , 2014, 37, 134-143.	4.3	18
111	Epigenetic modifications in prostate cancer. <i>Epigenomics</i> , 2014, 6, 415-426.	1.0	43
112	Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 3338-3347.	3.2	98
113	Instant equality fluorescence <i>in situ</i> hybridization as a new tool for HER2 testing in breast cancer: a comparative study. <i>Histopathology</i> , 2014, 64, 274-283.	1.6	12
114	Cancer cell autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. <i>Nature Medicine</i> , 2014, 20, 1301-1309.	15.2	823
115	HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. <i>Modern Pathology</i> , 2014, 27, 4-18.	2.9	236
116	Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACSO4 trial. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 789-800.	1.1	59
117	Lung cancer: how to face the revolution?. <i>Targeted Oncology</i> , 2013, 8, 1-2.	1.7	0
118	Early Telomere Shortening and Genomic Instability in Tubo-Ovarian Preneoplastic Lesions. <i>Clinical Cancer Research</i> , 2013, 19, 2873-2882.	3.2	36
119	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. <i>Annals of Oncology</i> , 2013, 24, 2206-2223.	0.6	2,805
120	An International Ki67 Reproducibility Study. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1897-1906.	3.0	498
121	Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 283-296.	1.1	22
122	Long-term Significance (15 years) of Pathological Complete Response after Dose-dense Neoadjuvant Chemotherapy in Breast Cancer. <i>Breast Journal</i> , 2013, 19, 448-450.	0.4	2
123	Change in HER2 (ERBB2) gene status after taxane-based chemotherapy for breast cancer: polyploidization can lead to diagnostic pitfalls with potential impact for clinical management. <i>Cancer Genetics</i> , 2013, 206, 37-41.	0.2	32
124	Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status. <i>Breast</i> , 2013, 22, 200-202.	0.9	19
125	<i>In vivo</i> efficacy of melanoma internal radionuclide therapy with a ¹³¹ I-labelled melanin-targeting heteroarylcarboxamide molecule. <i>International Journal of Cancer</i> , 2013, 133, 1042-1053.	2.3	25
126	Personalized medicine in oncology: where have we come from and where are we going?. <i>Pharmacogenomics</i> , 2013, 14, 931-939.	0.6	43

#	ARTICLE	IF	CITATIONS
127	Early Telomere Shortening and Genomic Instability in Tubo-Ovarian Preneoplastic Lesionsâ€”Response. <i>Clinical Cancer Research</i> , 2013, 19, 5255-5255.	3.2	4
128	Extended Benefit from Sequential Administration of Docetaxel after Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial. <i>Oncologist</i> , 2012, 17, 900-909.	1.9	28
129	Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH,) Tj ETQq1 1 0,784314 rgBT /Ove	2.9	42
130	HER2 testing in gastric cancer: a practical approach. <i>Modern Pathology</i> , 2012, 25, 637-650.	2.9	478
131	Contrasted Outcomes to Gefitinib on Tumoral IGF1R Expression in Head and Neck Cancer Patients Receiving Postoperative Chemoradiation (GORTEC Trial 2004-02). <i>Clinical Cancer Research</i> , 2012, 18, 5123-5133.	3.2	36
132	Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 1430-1437.	0.8	54
133	EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 461, 245-257.	1.4	198
134	Epidermal Growth Factor Receptor Protein Detection in Head and Neck Cancer Patients: A Many-Faceted Picture. <i>Clinical Cancer Research</i> , 2012, 18, 1313-1322.	3.2	37
135	Diagnostic performance of oneâ€”step nucleic acid amplification for intraoperative sentinel node metastasis detection in breast cancer patients. <i>International Journal of Cancer</i> , 2012, 130, 2377-2386.	2.3	52
136	Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 895-915.	1.1	246
137	Non sentinel node involvement prediction for sentinel node micrometastases in breast cancer: Nomogram validation and comparison with other models. <i>Breast</i> , 2012, 21, 204-209.	0.9	38
138	Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1656-1664.	3.0	1,505
139	Differential Impact of EGFR-Targeted Therapies on Hypoxia Responses: Implications for Treatment Sensitivity in Triple-Negative Metastatic Breast Cancer. <i>PLoS ONE</i> , 2011, 6, e25080.	1.1	30
140	Loss of p16INK4A Expression in Low-grade Ovarian Serous Carcinomas. <i>International Journal of Gynecological Pathology</i> , 2011, 30, 22-29.	0.9	16
141	Germline mutations of the Eâ€”cadherin gene in families with inherited invasive lobular breast carcinoma but no diffuse gastric cancer. <i>Cancer</i> , 2011, 117, 3112-3117.	2.0	60
142	HER2 diagnostics in gastric cancerâ€”guideline validation and development of standardized immunohistochemical testing. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010, 457, 299-307.	1.4	431
143	Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to antiâ€”EGFR antibodies in colorectal cancer. <i>International Journal of Cancer</i> , 2010, 127, 1321-1331.	2.3	45
144	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. <i>Lancet Oncology</i> , The, 2010, 11, 753-762.	5.1	1,915

#	ARTICLE	IF	CITATIONS
145	Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2809-2815.	0.8	214
146	Emerging Technologies for Assessing HER2 Amplification. <i>American Journal of Clinical Pathology</i> , 2009, 132, 539-548.	0.4	135
147	Trastuzumab for Patients With Axillary-Node-Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 6129-6134.	0.8	277
148	Targeted radionuclide therapy of melanoma: Antitumoural efficacy studies of a new ¹³¹ I labelled potential agent. <i>International Journal of Cancer</i> , 2009, 125, 708-716.	2.3	44
149	Increase in morphine antinociceptive activity by a P-glycoprotein inhibitor in cisplatin-induced neuropathy. <i>Neuroscience Letters</i> , 2009, 465, 108-112.	1.0	13
150	Value and Limitations of Measuring HER-2 Extracellular Domain in the Serum of Breast Cancer Patients. <i>Journal of Clinical Oncology</i> , 2009, 27, 1694-1705.	0.8	68
151	Metastatic Breast Cancer: Overall Survival Related to Successive Chemotherapies. What Do We Gain After the Third Line?. <i>Cancer Investigation</i> , 2009, 27, 81-85.	0.6	20
152	Analysis of <i>PTEN</i> , <i>BRAF</i> , and <i>EGFR</i> Status in Determining Benefit From Cetuximab Therapy in Wild-Type <i>KRAS</i> Metastatic Colon Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5924-5930.	0.8	645
153	Differential Expression of Biomarkers in Primary Non-small Cell Lung Cancer and Metastatic Sites. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1212-1220.	0.5	97
154	<i>KRAS</i> Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. <i>Journal of Clinical Oncology</i> , 2008, 26, 374-379.	0.8	1,398
155	Estrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2008, 26, 2636-2643.	0.8	54
156	Changes and Predictive and Prognostic Value of the Mitotic Index, Ki-67, Cyclin D1, and Cyclo-oxygenase-2 in 710 Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Oncologist</i> , 2008, 13, 1235-1245.	1.9	56
157	Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 268-278.	4.3	96
158	Leptin and leptin receptor involvement in cancer development: a study on human primary breast carcinoma. <i>Oncology Reports</i> , 2008, 19, 905-11.	1.2	93
159	Changes in and Prognostic Value of Hormone Receptor Status in a Series of Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Oncologist</i> , 2007, 12, 636-643.	1.9	76
160	Achieving Higher Pathological Complete Response Rates in HER2-Positive Patients With Induction Chemotherapy Without Trastuzumab in Operable Breast Cancer. <i>Oncologist</i> , 2007, 12, 390-396.	1.9	16
161	Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 Amplification. <i>Clinical Cancer Research</i> , 2007, 13, 6404-6409.	3.2	93
162	Stage I ovarian carcinoma: different clinical pathologic patterns. <i>Fertility and Sterility</i> , 2007, 88, 906-910.	0.5	40

#	ARTICLE	IF	CITATIONS
163	HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients. PLoS ONE, 2007, 2, e1138.	1.1	141
164	Standardization of HER2 testing: results of an international proficiency-testing ring study. Modern Pathology, 2007, 20, 584-591.	2.9	119
165	KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer. Cancer Research, 2006, 66, 3992-3995.	0.4	2,116
166	Sequential Addition of an Anthracycline-Based Regimen to Docetaxel as Neoadjuvant Chemotherapy in Patients with Operable Breast Cancer. Clinical Breast Cancer, 2006, 7, 262-269.	1.1	4
167	Randomized phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer. Urology, 2006, 67, 354-359.	0.5	24
168	Cost-effectiveness analysis of strategies for HER2 testing of breast cancer patients in France. International Journal of Technology Assessment in Health Care, 2006, 22, 396-401.	0.2	13
169	Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 281-287.	1.4	42
170	Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment?. Oncology Reports, 2006, 16, 1173-9.	1.2	32
171	Gene Expression Profiles Discriminate between Pathological Complete Response and Resistance to Neoadjuvant FEC100 in Breast Cancer. Cancer Genomics and Proteomics, 2006, 3, 89-95.	1.0	1
172	Patterns of P-glycoprotein activity in the nervous system during vincristine-induced neuropathy in rats. Journal of the Peripheral Nervous System, 2005, 10, 301-310.	1.4	32
173	High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Research and Treatment, 2005, 94, 255-263.	1.1	93
174	Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype. Clinical Cancer Research, 2005, 11, 5175-5180.	3.2	577
175	Pathological and Clinical Response of a Primary Chemotherapy Regimen Combining Vinorelbine, Epirubicin, and Paclitaxel as Neoadjuvant Treatment in Patients with Operable Breast Cancer. Oncologist, 2005, 10, 242-249.	1.9	11
176	Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers. Clinical Cancer Research, 2004, 10, 2473-2481.	3.2	224
177	Does 99mTc-Sestamibi Uptake Discriminate Breast Tumors?. Cancer Investigation, 2004, 22, 498-504.	0.6	9
178	Randomized Parallel Study of Doxorubicin Plus Paclitaxel and Doxorubicin Plus Cyclophosphamide As Neoadjuvant Treatment of Patients With Breast Cancer. Journal of Clinical Oncology, 2004, 22, 4958-4965.	0.8	138
179	Neoadjuvant FEC 100 for Operable Breast Cancer: Eight-Year Experience at Centre Jean Perrin. Clinical Breast Cancer, 2004, 5, 303-307.	1.1	14
180	Prophylactic oophorectomy. Cancer, 2003, 98, 2599-2606.	2.0	66

#	ARTICLE	IF	CITATIONS
181	Current Perspectives on HER2 Testing: A Review of National Testing Guidelines. <i>Modern Pathology</i> , 2003, 16, 173-182.	2.9	229
182	Prognostic Value of Residual Node Involvement in Operable Breast Cancer after Induction Chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2002, 76, 37-45.	1.1	71
183	Pgp immunochemistry: use with caution: correspondence re: C-H. Kao et al., P-glycoprotein and multidrug resistance-related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings. <i>Cancer Res.</i> , 61: 1412-1414, 2001. <i>Cancer Research</i> , 2002, 62, 617.	0.4	0
184	Interleukin-6 overexpression as a marker of malignancy in human gliomas. <i>Journal of Neurosurgery</i> , 2001, 94, 97-101.	0.9	109
185	WNT pathway and mammary carcinogenesis: Loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. <i>Oncogene</i> , 2001, 20, 5810-5817.	2.6	169
186	Antitumoral effect of interleukin-12-secreting fibroblasts in a mouse model of ovarian cancer: Implications for the use of ovarian cancer biopsy-derived fibroblasts as a vehicle for regional gene therapy. <i>Cancer Gene Therapy</i> , 2000, 7, 707-720.	2.2	16
187	Structural and Numerical Aberrations of Chromosome 22 in a Case of Follicular Variant of Papillary Thyroid Carcinoma Revealed by Conventional and Molecular Cytogenetics. <i>Cancer Genetics and Cytogenetics</i> , 2000, 121, 33-37.	1.0	14
188	Endometrial Histopathology in 700 Patients Treated with Tamoxifen for Breast Cancer. <i>Gynecologic Oncology</i> , 2000, 78, 181-186.	0.6	168
189	Quantification of RT-PCR Products: Ethidium Bromide-stained Gel Analysis Compared With Fluorescent Detection Using an Automated Sequencer. <i>Laboratory Medicine</i> , 1999, 30, 419-422.	0.8	4
190	O6-methylguanine-DNA methyltransferase gene(MGMT) expression in human glioblastomas in relation to patient characteristics and p53 accumulation. , 1999, 84, 416-420.		54
191	Expression of <i>fgf</i> and <i>fgf</i> receptor genes in human breast cancer. <i>International Journal of Cancer</i> , 1995, 61, 170-176.	2.3	213
192	The heregulin gene can be included in the 8p12 amplification unit in human breast cancer. <i>Genes Chromosomes and Cancer</i> , 1994, 11, 66-69.	1.5	7
193	Expression of the FGFR1 gene in human breast-carcinoma cells. <i>International Journal of Cancer</i> , 1994, 59, 373-378.	2.3	88